[Pomalidomide in the treatment of relapsed and refractory multiple myeloma]

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Multiple myeloma therapies have improved, but relapses and drug resistance remain significant challenges.
• Many patients develop disease refractory to standard treatments like lenalidomide and bortezomib, necessitating novel therapeutic approaches.
• Pomalidomide, a second-generation immunomodulatory agent, demonstrates potent anti-myeloma activity and unique mechanisms of action.

Purpose of the Study:

• To review the mechanism of action of pomalidomide.
• To summarize clinical trial data for pomalidomide in relapsed and refractory multiple myeloma.
• To explore novel pomalidomide-based combination therapies.

Main Methods:

• Review of existing literature on pomalidomide's mechanism of action.
• Analysis of clinical trial results for pomalidomide in multiple myeloma patients.
• Examination of safety and efficacy data, including adverse events.

Main Results:

• Pomalidomide exhibits direct anti-proliferative, pro-apoptotic, and antiangiogenic effects, with immunomodulatory and bone resorption effects.
• Clinical trials show pomalidomide plus low-dose dexamethasone yields superior outcomes compared to high-dose dexamethasone or pomalidomide monotherapy.
• Pomalidomide demonstrates limited cross-resistance with lenalidomide, with overall response rates of 26-31% in dual-refractory patients.
• Common grade 3/4 adverse events include neutropenia, thrombocytopenia, and anemia.

Conclusions:

• Pomalidomide is an effective treatment for relapsed/refractory multiple myeloma, particularly in patients resistant to lenalidomide and bortezomib.
• Combination therapy with low-dose dexamethasone enhances pomalidomide's efficacy.
• Pomalidomide has received regulatory approval for specific patient populations in multiple myeloma.